Clinical trial
Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or…
NCT00098865 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00098865 |
|---|---|
| Title | Thalidomide and Temozolomide in Relapsed or Progressive CNS Disease or Neuroblastoma |
| Official title | A Phase II Pilot Study Of Thalidomide With Temozolomide In Patients With Relapsed Or Progressive Brain Tumors Or Neuroblastoma |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH Boston Children's Hospital Celgene Corporation Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Central Nervous System Tumor, Pediatric, Neuroblastoma |
| Intervention type | Drug |
| Interventions | temozolomide, thalidomide |
| Enrollment | 15 |
| Start date | Sep 1, 2002 |
| Primary completion | Jun 1, 2010 |
| Completion | Jun 1, 2010 |
| First posted | Dec 9, 2004 |
| Last update posted | Oct 7, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: